11:05 AM EDT, 05/03/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We trim our 12-month target price by $1 to $32, reflecting 13.4x our 2025 EPS outlook, a discount to XRAY's five-year historical average given unfavorable macroeconomic conditions and competitive pressures on some of XRAY's businesses. We narrow our 2024 EPS forecast by $0.05 to $2.03 and widen our 2025 forecast by $0.02 to $2.38. XRAY reported Q1 EPS of $0.42 vs. $0.39, in line with the S&P Capital IQ consensus estimate. Sales of $953 million were narrowly below our expectations, with declines in imaging equipment where XRAY continues to experience the effects of market conditions and increased competition, offset by strong 53% growth in China, 14% growth in the Global aligners business, 9% growth in CAD/CAM and 5% growth in Wellspect HealthCare. We think further expansion into international markets, including Japan and Brazil, as well as cost savings and productivity initiatives, should help boost EPS growth in 2025.